1Gavras H,Brown JJ,Lever AF,et al.Acute renal failure,tubular necrosis and myocardial infarction induced in the rabbit by intravenous ANGiotensin Ⅱ[J].Lancet,1971,2:19.
2Bauer JH,Reams GP.The ANGiotensin Ⅱ type 1 receptor antagonists.A new class of antihypertensive drugs[J].Arch Intern Med,1995,155:1 361.
4Urate H,Strobel F,Ganten D.Widespread tissue distribution of human chymase[J].J Hypertens,1994,12:S17.
5Rodgers JE,Patterson JH.ANGiotensin Ⅱ receptor blocders:clinical relevance and therapeutic role[J].Am J Health Syst Pharm,2001,58(8):671-683.
6Oparil S.Comparative antihypertensive efficacy of olmesartan:comparison with other ANGiotensin Ⅱ receptor antagonists[J].J Hum Hypertens,2002,16(Supp12):S17-23.
7Shobha J C,Kumar T R,Raju B S,et al.Evaluation of efficacy and safety of losartan potassium in the treatment of mild to moderate hypertension as compared to enalapril maleate[J].J Assoc Plujsicians India,2000,48:497-500.
8Oparil S,Barr E,Elkins M,et al.Efficacy,tolerability,and effects on quality of life of losartan,alone or with hydro-chlorothiazide,in patients with essential hypertension[J].Clin Ther,1996,18:608.
9Corea L,Cardoni V,Fogari R,et al.Valsartan,a new ANGiotensin Ⅱ antagonist for the treatment of essential hypertension:Acomparative study of the efficacy and safety against amlodipine [J].Clin Pharmacol Ther,1996,60:341.
10Holwerde NJ,Fogari R,ANGeli P,et al.Valsartan,a new ANGiotensin Ⅱ antagonist for the treatment of essential hypertension:efficacy and safety compared with placebo and enalapril[J].J Hypertens,1996,14:1 147.
